{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T12:49:53Z","timestamp":1763988593992,"version":"3.41.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T00:00:00Z","timestamp":1744329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and purpose<\/jats:title>\n            <jats:p>In acromegaly, growth hormone (GH) excess and pituitary tumours are typically managed through transsphenoidal surgery, often in combination with somatostatin receptor ligands (SRLs) given either before or following surgery. Although first-generation SRLs (lanreotide and octreotide) are efficacious in many patients, some exhibit resistance.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>We present the efficacy of the second-generation SRL, pasireotide, in six patients anticipated to be resistant to first-generation SRLs. The patients had large, hyperintense tumors on T2-weighted MRI and sparse granulation pattern by histology.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Over three to eight months, pasireotide reduced tumour volume in all patients and improved GH and IGF-1 levels. Visual field defects normalised. Despite hyperglycemia, requiring antidiabetic treatment in two patients, pasireotide proved effective as a first pharmacological therapy.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This series supports the use of pasireotide for rapid tumour control and GH reduction, in selected patients with complex and large tumours, likely to be resistant to first-generation SRLs. This approach expands the therapeutic options for managing the most challenging cases enhancing the potential for other subsequent treatment modalities.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1007\/s11102-025-01514-3","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T20:28:32Z","timestamp":1744403312000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pasireotide as first line medical therapy for selected patients with acromegaly"],"prefix":"10.1007","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9436-539X","authenticated-orcid":false,"given":"Nicoleta C.","family":"Olarescu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1246-9194","authenticated-orcid":false,"given":"Anders P.","family":"J\u00f8rgensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6818-1076","authenticated-orcid":false,"given":"Shahriar","family":"Atai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4172-4115","authenticated-orcid":false,"given":"Markus K.H.","family":"Wiedmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5278-1978","authenticated-orcid":false,"given":"Daniel","family":"Dahlberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0654-4610","authenticated-orcid":false,"given":"Jens","family":"Bollerslev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3443-884X","authenticated-orcid":false,"given":"Ansgar","family":"Heck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,4,11]]},"reference":[{"key":"1514_CR1","doi-asserted-by":"publisher","DOI":"10.1007\/s11154-020-09588-z","author":"A Giustina","year":"2020","unstructured":"Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Melmed S (2020) Multidisciplinary management of acromegaly: A consensus. Rev Endocr Metab Disord. https:\/\/doi.org\/10.1007\/s11154-020-09588-z","journal-title":"Rev Endocr Metab Disord"},{"key":"1514_CR2","doi-asserted-by":"publisher","unstructured":"Petersenn S, Buchfelder M, Reincke M, Strasburger CM, Franz H, Lohmann R, Register (2008) t.P.o.t.G.A.: Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German acromegaly register. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/eje-08-0498","DOI":"10.1530\/eje-08-0498"},{"key":"1514_CR3","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0124","author":"J Bollerslev","year":"2019","unstructured":"Bollerslev J, Heck A, Olarescu NC (2019) MANAGEMENT OF ENDOCRINE DISEASE: individualised management of acromegaly. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-19-0124","journal-title":"Eur J Endocrinol"},{"key":"1514_CR4","doi-asserted-by":"publisher","DOI":"10.3171\/2017.12.JNS172318","author":"MS Agam","year":"2019","unstructured":"Agam MS, Wedemeyer MA, Wrobel B, Weiss MH, Carmichael JD, Zada G (2019) Complications associated with microscopic and endoscopic transsphenoidal pituitary surgery: experience of 1153 consecutive cases treated at a single tertiary care pituitary center. J Neurosurg. https:\/\/doi.org\/10.3171\/2017.12.JNS172318","journal-title":"J Neurosurg"},{"key":"1514_CR5","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0762","author":"AAL Colao","year":"2020","unstructured":"Colao AAL, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Gadelha MR (2020) Pasireotide for acromegaly: long-term outcomes from an extension to the phase III (PAOLA) study. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-19-0762","journal-title":"Eur J Endocrinol"},{"key":"1514_CR6","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.648411","author":"M Puig-Domingo","year":"2021","unstructured":"Puig-Domingo M, Bernabeu I, Pico A, Biagetti B, Gil J, Alvarez-Escola C, Marazuela M (2021) Pasireotide in the personalized treatment of acromegaly. Front Endocrinol (Lausanne). https:\/\/doi.org\/10.3389\/fendo.2021.648411","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1514_CR7","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-015-0766-8","author":"A Heck","year":"2015","unstructured":"Heck A, Emblem KE, Casar-Borota O, Bollerslev J, Ringstad G (2015) Quantitative analyses of T2-weighted MRI as a potential marker for response to somatostatin analogs in newly diagnosed acromegaly. Endocrine. https:\/\/doi.org\/10.1007\/s12020-015-0766-8","journal-title":"Endocrine"},{"key":"1514_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1269787","author":"M Marques-Pamies","year":"2023","unstructured":"Marques-Pamies M, Gil J, Valassi E, Hern\u00e1ndez M, Biagetti B, Gim\u00e9nez-Palop O, Puig-Domingo M (2023) Revisiting the usefulness of the short acute octreotide test to predict treatment outcomes in acromegaly. Front Endocrinol. https:\/\/doi.org\/10.3389\/fendo.2023.1269787","journal-title":"Front Endocrinol"},{"key":"1514_CR9","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14946","author":"S Ruiz","year":"2023","unstructured":"Ruiz S, Gil J, Biagetti B, Venegas E, C\u00e1mara R, Garcia-Centeno R, Puig-Domingo M (2023) Magnetic resonance imaging as a predictor of therapeutic response to Pasireotide in acromegaly. Clin Endocrinol. https:\/\/doi.org\/10.1111\/cen.14946","journal-title":"Clin Endocrinol"},{"key":"1514_CR10","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-014-0383-y","author":"K Kiseljak-Vassiliades","year":"2015","unstructured":"Kiseljak-Vassiliades K, Carlson NE, Borges MT, Kleinschmidt-DeMasters BK, Lillehei KO, Kerr JM, Wierman ME (2015) Growth hormone tumor histological subtypes predict response to surgical and medical therapy. Endocrine. https:\/\/doi.org\/10.1007\/s12020-014-0383-y","journal-title":"Endocrine"},{"key":"1514_CR11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2265.2011.04286.x","author":"A Heck","year":"2012","unstructured":"Heck A, Ringstad G, Fougner SL, Casar-Borota O, Nome T, Ramm-Pettersen J, Bollerslev J (2012) Intensity of pituitary adenoma on T2-weighted magnetic resonance imaging predicts the response to octreotide treatment in newly diagnosed acromegaly. Clin Endocrinol (Oxf). https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04286.x","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1514_CR12","doi-asserted-by":"crossref","unstructured":"Knosp E, Steiner E, Kitz K, Matula C (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/8232800","DOI":"10.1227\/00006123-199310000-00008"},{"key":"1514_CR13","doi-asserted-by":"publisher","unstructured":"Raverot G, Burman P, McCormack A, Heaney A, Petersenn S, Popovic V (2018) European Society of, E.: European Society of Endocrinology Clinical Practice Guidelines for the management of aggressive pituitary tumours and carcinomas. Eur J Endocrinol https:\/\/doi.org\/10.1530\/EJE-17-0796","DOI":"10.1530\/EJE-17-0796"},{"key":"1514_CR14","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-2480","author":"A Colao","year":"2014","unstructured":"Colao A, Bronstein MD, Freda P, Gu F, Shen CC, Gadelha M, Pasireotide CSG (2014) Pasireotide versus octreotide in acromegaly: a head-to-head superiority study. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/jc.2013-2480","journal-title":"J Clin Endocrinol Metab"},{"key":"1514_CR15","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0487","author":"R Yamamoto","year":"2018","unstructured":"Yamamoto R, Shima KR, Igawa H, Kaikoi Y, Sasagawa Y, Hayashi Y, Takamura T (2018) Impact of preoperative Pasireotide therapy on invasive octreotide-resistant acromegaly. Endocr J. https:\/\/doi.org\/10.1507\/endocrj.EJ17-0487","journal-title":"Endocr J"},{"key":"1514_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s12020-019-01874-4","author":"S Chiloiro","year":"2019","unstructured":"Chiloiro S, Giampietro A, Bianchi A, Tartaglione T, Bima C, Vita MG, De Marinis L (2019) Acromegaly can be cured by first-line Pasireotide treatment? Endocrine. https:\/\/doi.org\/10.1007\/s12020-019-01874-4","journal-title":"Endocrine"},{"key":"1514_CR17","unstructured":"European Medicines Agency. Signifor (2012) [cited 2024 16.09.2024]; Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/signifor-epar-product-information_en.pdf"},{"key":"1514_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(14)70169-X","author":"MR Gadelha","year":"2014","unstructured":"Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pasireotide CSG (2014) Pasireotide versus continued treatment with octreotide or Lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial. Lancet Diabetes Endocrinol. https:\/\/doi.org\/10.1016\/S2213-8587(14)70169-X","journal-title":"Lancet Diabetes Endocrinol"},{"key":"1514_CR19","doi-asserted-by":"publisher","DOI":"10.1530\/eje-15-0832","author":"D Iacovazzo","year":"2016","unstructured":"Iacovazzo D, Carlsen E, Lugli F, Chiloiro S, Piacentini S, Bianchi A, De Marinis L (2016) Factors predicting Pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/eje-15-0832","journal-title":"Eur J Endocrinol"},{"key":"1514_CR20","doi-asserted-by":"publisher","DOI":"10.1530\/erc-16-0356","author":"I Potorac","year":"2016","unstructured":"Potorac I, Petrossians P, Daly AF, Alexopoulou O, Borot S, Sahnoun-Fathallah M, Beckers A (2016) T2-weighted MRI signal predicts hormone and tumor responses to somatostatin analogs in acromegaly. Endocrine-related Cancer. https:\/\/doi.org\/10.1530\/erc-16-0356","journal-title":"Endocrine-related Cancer"},{"key":"1514_CR21","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-20-0767","author":"S Chiloiro","year":"2021","unstructured":"Chiloiro S, Giampietro A, Mirra F, Donfrancesco F, Tartaglione T, Mattogno PP, Bianchi A (2021) Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. Eur J Endocrinol. https:\/\/doi.org\/10.1530\/EJE-20-0767","journal-title":"Eur J Endocrinol"},{"key":"1514_CR22","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgac512","author":"M-D Ilie","year":"2022","unstructured":"Ilie M-D, Tabarin A, Vasiljevic A, Bonneville J-F, Moreau-Grang\u00e9 L, Schillo F, Raverot G (2022) Predictive factors of somatostatin receptor ligand response in Acromegaly\u2014A prospective study. J Clin Endocrinol Metabolism. https:\/\/doi.org\/10.1210\/clinem\/dgac512","journal-title":"J Clin Endocrinol Metabolism"},{"key":"1514_CR23","doi-asserted-by":"publisher","unstructured":"Fleseriu M, Rusch E, Geer EB, Investigators AS (2017) Safety and tolerability of pasireotide long-acting release in acromegaly-results from the acromegaly, open-label, multicenter, safety monitoring program for treating patients who have a need to receive medical therapy (ACCESS) study. Endocrine https:\/\/doi.org\/10.1007\/s12020-016-1182-4","DOI":"10.1007\/s12020-016-1182-4"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-025-01514-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-025-01514-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T19:19:08Z","timestamp":1751397548000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-025-01514-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,11]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1514"],"URL":"https:\/\/doi.org\/10.1007\/s11102-025-01514-3","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"type":"print","value":"1386-341X"},{"type":"electronic","value":"1573-7403"}],"subject":[],"published":{"date-parts":[[2025,4,11]]},"assertion":[{"value":"5 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"N.C.O. received speaker fees from CORE2ED (supported by a medical education grant from Ipsen) in 2021. A.H. received lecture fees and participated in two advisory board meetings for Recordati in 2021.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"48"}}